Search Results - "Knapen, Lotte M"

Development and validation of an analytical method using UPLC–MS/MS to quantify everolimus in dried blood spots in the oncology setting by Knapen, Lotte M., Beer, Yvo de, Brüggemann, Roger J.M., Stolk, Leo M., Vries, Frank de, Tjan-Heijnen, Vivianne C.G., Erp, Nielka P.van, Croes, Sander

“…•An everolimus DBS method for the oncology setting was developed and validated.•The method was validated according to the EMA guidelines for bioanalytical…”
Get full text

Use of biguanides and the risk of colorectal cancer: a register-based cohort study by Knapen, Lotte M, Dittrich, Suzanne T A M, de Vries, Frank, Starup-Linde, Jakob, Vestergaard, Peter, Henry, Ronald M A, Stolk, Leo M L, Neef, Cees, Bazelier, Marloes T

“…Observational studies have shown conflicting results on the potential protecting effect of biguanide use with the risk of colorectal neoplasms. In addition,…”
Get more information

Plasma Concentrations of Tyrosine Kinase Inhibitors Imatinib, Erlotinib, and Sunitinib in Routine Clinical Outpatient Cancer Care by LANKHEET, Nienke A. G, KNAPEN, Lotte M, SCHELLENS, Jan H. M, BEIJNEN, Jos H, STEEGHS, Neeltje, HUITEMA, Alwin D. R

“…The objectives of this study were to evaluate the plasma concentrations of the tyrosine kinase inhibitors (TKIs), imatinib, erlotinib, and sunitinib, in a…”
Get full text

Use of incretin agents and risk of acute and chronic pancreatitis: A population‐based cohort study by Knapen, Lotte M., de Jong, Roy G. P. J., Driessen, Johanna H. M., Keulemans, Yolande C., van Erp, Nielka P., De Bruin, Marie L., Leufkens, Hubert G. M., Croes, Sander, de Vries, Frank

“…Aim To determine the association between the use of incretin agents (dipeptidyl peptidase‐4 inhibitors and glucagon‐like peptide‐1 receptor agonists) for the…”
Get full text

Thiazolodinediones and Cancer: Duplicate Publication Bias? by Vries, Frank, Zeegers, Maurice P., Knapen, Lotte M., Goossens, Maria E.

“…A meta‐analysis of epidemiological studies reported no increased risk for cancer in users of thiazolidinediones; however, subanalyses showed a small 1.1‐ to…”
Get full text

The Impact of Dose and Simultaneous Use of Acid-Reducing Agents on the Effectiveness of Vemurafenib in Metastatic BRAF V600 Mutated Melanoma: a Retrospective Cohort Study by Knapen, Lotte M., Koornstra, Rutger H. T., Driessen, Johanna H. M., van Vlijmen, Bas, Croes, Sander, Schalkwijk, Stein, Colbers, Angela, Gerritsen, Winald R., Burger, David M., de Vries, Frank, van Erp, Nielka P.

“…Background The impact of dose and simultaneous use of acid-reducing agents (ARAs) on the effectiveness of vemurafenib is unknown. Objectives To determine the…”
Get full text